A pharma giant is moving past one patent cliff — but another is already looming

The Quick Take
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to CNBC Top News.

